Stocks Health care MDT
NYSE · Health careMedtronic plc (MDT)
Medtronic plc brought in $37.5B of revenue over the twelve months to July 31, 2026, up 9.8% from a year earlier. Net income was $5.2B, a net margin of 13.9%. Operating cash flow minus capital spending left $5.4B of free cash flow in fiscal 2026. At July 31, 2026 it held $1.7B in cash against $25.6B of debt.
Key facts about Medtronic plc
- Net worth
- Medtronic plc has a market value (market cap) of $130B at the latest share price, and shareholders' equity of $50.2B on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $36.4B (+8.4% year on year), with net income of $4.8B. Over the 12 months to July 31, 2026: revenue $37.5B, net income $5.2B.
- Cash flow
- In fiscal 2026 operations brought in $7.3B of cash; after $1.9B of capital spending, free cash flow was $5.4B.
- Dividend
- Medtronic plc declared dividends of $2.84 per share in fiscal 2026, a yield of 2.80% at the current price.
What Medtronic plc does
Medtronic designs and manufactures medical devices and therapeutic technologies. Its products include pacemakers, insulin pumps, surgical tools, and spinal implants. These devices are purchased by hospitals, clinics, and healthcare providers to treat cardiovascular, neurological, and metabolic conditions. Its shares trade on NYSE under the ticker MDT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $36.4B | $4.8B | $3.73 | $5.4B |
| 2025 | $33.5B | $4.7B | $3.61 | $5.2B |
| 2024 | $32.4B | $3.7B | $2.76 | $5.2B |
| 2023 | $31.2B | $3.8B | $2.82 | $4.6B |
| 2022 | $31.7B | $5B | $3.73 | $6B |
| 2021 | $30.1B | $3.6B | $2.66 | $4.9B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MDT ranks in Health care
Dividends
Medtronic plc declared $2.84 per share in fiscal 2026. At the current price that is a yield of 2.80%. It paid out $3.6B in cash dividends, 76% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2026 | $2.84 | $3.6B | 76% |
| 2025 | $2.80 | $3.6B | 77% |
| 2024 | $2.76 | $3.7B | 100% |
| 2023 | $2.72 | $3.6B | 96% |
| 2022 | $2.52 | $3.4B | 67% |
| 2021 | $2.32 | $3.1B | 87% |
Latest SEC filings
What Medtronic plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 21, 2026
- October 21, 2026
- October 19, 2026
- October 16, 2026Passive stake changed SCHEDULE 13G/A
- October 14, 2026Form SC TO-I/A filing SC TO-I/A
- October 14, 2026Form 425 filing 425
- October 13, 2026Form SC TO-I/A filing SC TO-I/A
- October 13, 2026Form 425 filing 425
- October 9, 2026Form 425 filing 425
- October 8, 2026Form 425 filing 425
What is MDT worth? A DCF from its reported cash flow
Insider trades
What the people running Medtronic plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5.9M worth of shares in the last 90 days and bought none on the open market. Most of the selling (98%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Marinaro MichaelPresident | Received as pay | 6,547 | - |
| October 15, 2026 | Lofton Kevin EDirector | Other change | 182 | - |
| October 15, 2026 | Martha GeoffreyChairman and CEO, Director | Soldpre-planned (10b5-1) | 50,000 | $4.8M |
| October 15, 2026 | Marinaro MichaelEVP, Pres MedSurg and Americas | Soldpre-planned (10b5-1) | 10,420 | $1M |
| September 16, 2026 | Kiil Harry SkipEVP & President Cardiovascular | Sold | 1,483 | $138.9K |
| September 15, 2026 | Blomquist Denise L.Chief Accounting Officer | Gave as a gift | 600 | - |
| August 20, 2026 | Marinaro MichaelEVP, Pres MedSurg and Americas | Shares withheld for tax | 1,084 | $100.1K |
| August 3, 2026 | Martha GeoffreyChairman and CEO, Director | Received as pay | 41,533 | - |
Who owns MDT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Medtronic plc13G, passive | 90% | May 6, 2026 |
| Vanguard Capital Management13G, passive | 7.51% | April 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 2,145 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 116,017,276 | +2,808,534 |
| Vanguard Capital Management LLC | 84,140,060 | +806,227 |
| State Street Corp | 63,802,604 | +2,061,590 |
| Massachusetts Financial Services Co | 28,207,338 | -108,721 |
| Vanguard Portfolio Management LLC | 34,253,014 | +802,456 |
| Geode Capital Management, LLC | 31,148,039 | +2,165,767 |
| Jpmorgan Chase & Co | 27,796,402 | -23,177,139 |
| First Eagle Investment Management, LLC | 27,567,966 | +17,523,271 |
| Bank of America Corp | 21,561,220 | -4,503,846 |
| Morgan Stanley | 19,515,951 | -1,244,216 |
| Deutsche Bank AG\ | 18,477,950 | -524,464 |
| Invesco Ltd. | 17,903,840 | +1,116,842 |
| Franklin Resources Inc | 17,550,983 | +3,375,304 |
| Norges Bank | 18,512,018 | new |
| Royal Bank of Canada | 16,027,651 | +1,847,834 |
| Bank of New York Mellon Corp | 14,765,051 | -736,818 |
| Capital Research Global Investors | 13,261,310 | -28,665,280 |
| Arrowstreet Capital, Limited Partnership | 12,892,710 | +8,233,285 |
| Northern Trust Corp | 11,854,674 | -182,147 |
| Ameriprise Financial Inc | 11,565,988 | -413,943 |
Insiders
21 insiders reported holding 948,578 shares in total, about $96.4M at the last price.
| Holder | Shares |
|---|---|
| Martha GeoffreyChairman and CEO, Director | 277,866 |
| Marinaro MichaelPresident | 113,353 |
| Wall Brett A.EVP & Pres Neuroscience | 82,183 |
| Powell Kendall JDirector | 51,380 |
| Pieton ThierryEVP & Chief Financial Officer | 49,645 |
| Hogan Randall JDirector | 48,998 |
| Smith Gregory LEVP Global Ops & Supply Chain | 46,016 |
| Kiil Harry SkipEVP & President Cardiovascular | 42,186 |
| Arnold CraigDirector | 42,185 |
| Walter Matthew R.SVP, Chief HR Officer | 39,928 |
Questions about MDT
What does Medtronic plc do?
Medtronic designs and manufactures medical devices and therapeutic technologies. Its products include pacemakers, insulin pumps, surgical tools, and spinal implants. These devices are purchased by hospitals, clinics, and healthcare providers to treat cardiovascular, neurological, and metabolic conditions. Its shares trade on NYSE under the ticker MDT.
What is Medtronic plc's net worth?
Medtronic plc has a market value (market cap) of $130B at the latest share price, and shareholders' equity of $50.2B on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Medtronic plc profitable?
Yes. Over the twelve months to July 31, 2026 it reported net income of $5.2B on revenue of $37.5B, a net margin of 13.9%.
How much revenue does Medtronic plc make?
Over the twelve months to July 31, 2026 Medtronic plc reported revenue of $37.5B. That is 9.8% more than a year earlier.
When did Medtronic plc last report?
Its newest filing of any kind is the insider trade from November 4, 2026.
Does Medtronic plc pay a dividend?
Yes. Medtronic plc declared dividends of $2.84 per share in fiscal 2026, a yield of 2.80% at the current price.
Similar companies
Compare MDT with
Follow MDT
Get an email when Medtronic plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Medtronic plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.